References
- Simon A, Asli B, Braun-Falco M, et al. Schnitzler’s syndrome: diagnosis, treatment and follow-up. Allergy. 2013;68(5):1–4. doi: 10.1111/all.12129.
- Lipsker D. The schnitzler syndrome. Orphanet J Rare Dis. 2010;5(1):38. doi: 10.1186/1750-1172-5-38.
- Rowczenio DM, Pathak S, Arostegui JI, et al. Molecular genetic investigation, clinical features and response to treatment in 21 patients with schnitzler syndrome. Blood. 2018;131(9):974–981. doi: 10.1182/blood-2017-10-810366.
- De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, et al. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in schnitzler’s syndrome. Ann Rheum Dis. 2013;72(10):1634–1638. doi: 10.1136/annrheumdis-2012-202192.
- Krause K, Tsianakas A, Wagner N, et al. Efficacy and safety of canakinumab in schnitzler syndrome: a multicenter randomized placebo-controlled study. J Allergy Clin Immunol. 2017;139(4):1311–1320. doi: 10.1016/j.jaci.2016.07.041.
- Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10(10):19. doi: 10.1186/s13023-015-0228-7.
- Gusdorf L, Lipsker D. Schnitzler syndrome: a review. Curr Rheumatol Rep. 2017;19(8):46. doi: 10.1007/s11926-017-0673-5.
- Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550. doi: 10.1146/annurev.immunol.021908.132612.
- Loock J, Lamprecht P, Timmann C, et al. Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with schnitzler syndrome. J Allergy Clin Immunol. 2010;125(2):500–502. doi: 10.1016/j.jaci.2009.10.066.
- Martínez-Taboada VM, Fontalba A, Blanco R, et al. Successful treatment of refractory schnitzler syndrome SchS with anakinra: comment on the article by hawkings et al. Arthritis Rheum. 2005;52(7):2226–2227. doi: 10.1002/art.21101.
- Néel A, Henry B, Barbarot S, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in schnitzler’s syndrome: a french multicenter study. Autoimmun Rev. 2014;13(10):1035–1041. doi: 10.1016/j.autrev.2014.08.031.
- Gouveia AI, Micaelo M, Pierdomenico F, et al. Schnitzler síndrome: a dramatic response to anakinra. Dermatol Ther (Heidelb). 2016;6(2):299–302. doi: 10.1007/s13555-016-0108-7.
- Betrains A, Staels F, Vanderschueren S. Efficacy and safety of canakinumab treatment in schnitzler syndrome: a systematic literature review. Semin Arthritis Rheum. 2020;50(4):636–642. doi: 10.1016/j.semarthrit.2020.05.002.
- Vanderschueren S, Knockaert D. Canakinumab in schnitzler syndrome. Semin Arthritis Rheum. 2013;42(4):413–416. doi: 10.1016/j.semarthrit.2012.06.003.
- Krause K, Bonnekoh H, Ellrich A, et al. Long-term efficacy of canakinumab in the treatment of schnitzler syndrome. J Allergy Clin Immunol. 2020;145(6):1681–1686.e5. doi: 10.1016/j.jaci.2019.12.909.
- de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4(4):41. doi: 10.1186/2045-7022-4-41.
- Gellrich FF, Günther C. Schnitzler syndrome. Hautarzt. 2019;5 doi: 10.1007/s00105-019-4434-4.
- Pesek R, Fox R. Successful treatment of schnitzler syndrome with canakinumab. Cutis. 2014;94(3):E11–2.
- Thomsen SF, Duhn PH, Kristensen J. A 51-Year old woman with schnitzler syndrome treated with canakinumab. Open Dermatol J. 2011;5:31–32.